| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Immunology Program and Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh PA 15261; and
Biology Department, Washington and Jefferson College, Washington, PA 15301
Low-frequency CTL and low-titer IgM responses against tumor-associated Ag MUC1 are present in cancer patients but do not prevent cancer growth. Boosting MUC1-specific immunity with vaccines, especially effector mechanisms responsible for tumor rejection, is an important goal. We studied immunogenicity, tumor rejection potential, and safety of three vaccines: 1) MUC1 peptide admixed with murine GM-CSF as an adjuvant; 2) MUC1 peptide admixed with adjuvant SB-AS2; and 3) MUC1 peptide-pulsed dendritic cells (DC). We examined the qualitative and quantitative differences in humoral and T cell-mediated MUC1-specific immunity elicited in human MUC1-transgenic (Tg) mice compared with wild-type (WT) mice. Adjuvant-based vaccines induced MUC1-specific Abs but failed to stimulate MUC1-specific T cells. MUC1 peptide with GM-CSF induced IgG1 and IgG2b in WT mice but only IgM in MUC1-Tg mice. MUC1 peptide with SB-AS2 induced high-titer IgG1, IgG2b, and IgG3 Abs in both WT and MUC1-Tg mice. Induction of IgG responses was T cell independent and did not have any effect on tumor growth. MUC1 peptide-loaded DC induced only T cell immunity. If injected together with soluble peptide, the DC vaccine also triggered Ab production. Importantly, the DC vaccine elicited tumor rejection responses in both WT and MUC1-Tg mice. These responses correlated with the induction of MUC1-specific CD4+ and CD8+ T cells in WT mice, but only CD8+ T cells in MUC1-Tg mice. Even though MUC1-specific CD4+ T cell tolerance was not broken, the capacity of MUC1-Tg mice to reject tumor was not compromised.
This article has been cited by other articles:
|
|
 |
|
  O. J. Finn Immunological Weapons Acquired Early in Life Win Battles with Cancer Late in Life J. Immunol., August 1, 2008; 181(3): 1589 - 1592. [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cloosen, J. Arnold, M. Thio, G. M.J. Bos, B. Kyewski, and W. T.V. Germeraad Expression of Tumor-Associated Differentiation Antigens, MUC1 Glycoforms and CEA, in Human Thymic Epithelial Cells: Implications for Self-Tolerance and Tumor Therapy Cancer Res., April 15, 2007; 67(8): 3919 - 3926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Turner, P. A. Cohen, and O. J. Finn Lack of Effective MUC1 Tumor Antigen-Specific Immunity in MUC1-Transgenic Mice Results from a Th/T Regulatory Cell Imbalance That Can Be Corrected by Adoptive Transfer of Wild-Type Th Cells J. Immunol., March 1, 2007; 178(5): 2787 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin J. Immunol., December 15, 2006; 177(12): 8410 - 8421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Sorensen, C. A. Reis, M. A. Tarp, U. Mandel, K. Ramachandran, V. Sankaranarayanan, T. Schwientek, R. Graham, J. Taylor-Papadimitriou, M. A. Hollingsworth, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance Glycobiology, February 1, 2006; 16(2): 96 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gerloni, P. Castiglioni, and M. Zanetti The Cooperation between Two CD4 T Cells Induces Tumor Protective Immunity in MUC.1 Transgenic Mice J. Immunol., November 15, 2005; 175(10): 6551 - 6559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Robertson, H.-C. Chang, D. Pelloso, and M. H. Kaplan Impaired interferon-{gamma} production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma Blood, August 1, 2005; 106(3): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Herbert, J. F. Grosso, M. Dorsey Jr., T. Fu, I. Keydar, M. A. Cejas, D. H. Wreschner, N. Smorodinski, and D. M. Lopez A Unique Mucin Immunoenhancing Peptide with Antitumor Properties Cancer Res., November 1, 2004; 64(21): 8077 - 8084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cloosen, M. Thio, A. Vanclee, E. B. M. van Leeuwen, B. L. M. G. Senden-Gijsbers, E. B. H. Oving, W. T. V. Germeraad, and G. M. J. Bos Mucin-1 is expressed on dendritic cells, both in vitro and in vivo Int. Immunol., November 1, 2004; 16(11): 1561 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. T. Marcos, S. Pinho, C. Grandela, A. Cruz, B. Samyn-Petit, A. Harduin-Lepers, R. Almeida, F. Silva, V. Morais, J. Costa, et al. Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen Cancer Res., October 1, 2004; 64(19): 7050 - 7057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hong, J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N.-K. V. Cheung, and G. D. Ross Mechanism by Which Orally Administered {beta}-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models J. Immunol., July 15, 2004; 173(2): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Monti, B. E. Leone, A. Zerbi, G. Balzano, S. Cainarca, V. Sordi, M. Pontillo, A. Mercalli, V. Di Carlo, P. Allavena, et al. Tumor-Derived MUC1 Mucins Interact with Differentiating Monocytes and Induce IL-10highIL-12low Regulatory Dendritic Cell J. Immunol., June 15, 2004; 172(12): 7341 - 7349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross {beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells Cancer Res., December 15, 2003; 63(24): 9023 - 9031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Premalignant Lesions as Targets for Cancer Vaccines J. Exp. Med., December 1, 2003; 198(11): 1623 - 1626. [Full Text] [PDF]
|
|
|
|
|
|
J. Li, W. Li, S. Liang, D. Cai, M. P. Kieny, L. Jacob, A. Linnenbach, J. W. Abramczuk, H. Bender, K. Sproesser, et al. Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice J. Immunol., September 15, 2003; 171(6): 2922 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sato, K. Chamoto, and T. Nishimura A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells Int. Immunol., July 1, 2003; 15(7): 837 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma Clin. Cancer Res., June 1, 2003; 9(6): 2213 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Chung, Y. Luo, M. O'Donnell, C. Rodriguez, W. Heber, S. Sharma, and H. R. Chang Development and Preclinical Evaluation of a Bacillus Calmette-Guerin-MUC1-based Novel Breast Cancer Vaccine Cancer Res., March 15, 2003; 63(6): 1280 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vlad, S. Muller, M. Cudic, H. Paulsen, L. Otvos Jr., F.-G. Hanisch, and O. J. Finn Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells: Processing of Tumor Antigen MUC1 Glycopeptides for Presentation to Major Histocompatibility Complex Class II-restricted T Cells J. Exp. Med., December 2, 2002; 196(11): 1435 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mulryan, M. G. Ryan, K. A. Myers, D. Shaw, W. Wang, S. M. Kingsman, P. L. Stern, and M. W. Carroll Attenuated Recombinant Vaccinia Virus Expressing Oncofetal Antigen (Tumor-associated Antigen) 5T4 Induces Active Therapy of Established Tumors Mol. Cancer Ther., October 1, 2002; 1(12): 1129 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
